Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more
Sionna Therapeutics, Inc. Common Stock (SION) - Total Liabilities
Latest total liabilities as of September 2025: $17.60 Million USD
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has total liabilities worth $17.60 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sionna Therapeutics, Inc. Common Stock - Total Liabilities Trend (2022–2024)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sionna Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Qianjiang Motorcycle Co Ltd
SHE:000913
|
China | CN¥5.81 Billion |
|
Ningxia Western Venture Industrial Co Ltd
SHE:000557
|
China | CN¥597.32 Million |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
China | CN¥1.40 Billion |
|
Sekerbank TAS
IS:SKBNK
|
Turkey | TL152.40 Billion |
|
NOS S.G.P.S. S.A
PINK:ZONNF
|
USA | $2.49 Billion |
|
Jiangsu SOPO Chemical Co Ltd
SHG:600746
|
China | CN¥1.37 Billion |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
China | CN¥876.89 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down Sionna Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sionna Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sionna Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual total liabilities of Sionna Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $349.46 Million | +109.48% |
| 2023-12-31 | $166.83 Million | +6.06% |
| 2022-12-31 | $157.29 Million | -- |